Parkinson's disease
Conditions
Interventions
experimental group:Pramipexol + dopa hydrazine combination therapy
control group: dopa hydrazine
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: From October 2020 to March 2022, 100 pD-RBD patients older than 18 years old were selected and admitted to Parkinson's Disease outpatient department and ward of Neurology Department of Shanghai First People's Hospital. (1) According to the diagnostic criteria and differential diagnosis of Parkinson's disease and Parkinson's Syndrome, patients with primary PD and RBD were diagnosed; (2) RBD Screening Questionnaire (RBDSQ) total score >= 6 points; (3) No ergoid or non-ergoid dopamine receptor agonist was used for treatment; (4) Basic communication skills, can cooperate with the treatment; (5) Know the research and sign the consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with dementia, cerebral hemorrhage, and mental disorders; (2) Patients with severe liver, kidney and cardiac insufficiency; (3) Various secondary PD syndromes and PD superposition syndromes; (4) PD patients who are not treated with compound LD preparation or who are not responding to the treatment with compound LD preparation; (5) Irregular medication or poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of disease condition and curative effect;Adverse reactions;Serum inflammatory factors; | — |
Countries
China
Contacts
Public ContactZhou Yan
Shanghai General Hospital
Outcome results
None listed